{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:01:13Z","timestamp":1784937673345,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmed.2026.108826","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:34:48Z","timestamp":1776494088000},"page":"108826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcomes of patients with COPD before and after initiation of treatment with budesonide\/glycopyrrolate\/formoterol fumarate: Results from the US ARCTOS study"],"prefix":"10.1016","volume":"257","author":[{"given":"Sanjay","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gozalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McMorrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Feigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Spy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Hirpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tkacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-6301","authenticated-orcid":false,"given":"Hayley D.","family":"Germack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9589","key":"10.1016\/j.rmed.2026.108826_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2026.108826_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2019.10241","article-title":"Prevalence and treatment of chronic obstructive Pulmonary Disease (COPD) in the United States","volume":"322","author":"Biener","year":"2019","journal-title":"JAMA"},{"issue":"46","key":"10.1016\/j.rmed.2026.108826_bib3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.15585\/mmwr.mm7246a1","article-title":"Trends in the prevalence of chronic obstructive pulmonary disease among adults aged >\/=18 years - united States, 2011-2021","volume":"72","author":"Liu","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.rmed.2026.108826_bib4","article-title":"GOLD report: global strategy for prevention","year":"2026","journal-title":"Diagnosis and Management of COPD: 2026 Report"},{"issue":"12","key":"10.1016\/j.rmed.2026.108826_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.14-0972","article-title":"Total and state-specific medical and absenteeism costs of COPD among adults aged >\/= 18 years in the United States for 2010 and projections through 2020","volume":"147","author":"Ford","year":"2015","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2026.108826_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chest.2023.11.040","article-title":"National and Local Direct Medical Cost Burden of COPD in the United States from 2016 to 2019 and Projections through 2029","volume":"165","author":"Mannino","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13561-021-00329-9","article-title":"Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review","volume":"11","author":"Gutierrez","year":"2021","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.rmed.2026.108826_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/COPD.S234942","article-title":"Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review","volume":"15","author":"Iheanacho","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2026.108826_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US Study","volume":"19","author":"Daniels","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2026.108826_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/COPD.S350248","article-title":"Relationship of COPD exacerbation severity and frequency on risks for future events and economic burden in the Medicare fee-for-service population","volume":"17","author":"Sethi","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12931-018-0944-3","article-title":"Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial","volume":"19","author":"Watz","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108826_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/COPD.S378867","article-title":"COPD exacerbations, costs, and health care resource utilization before and after initiation of Fluticasone Furoate\/Umeclidinium\/Vilanterol in routine care in the USA","volume":"18","author":"Hanania","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2026.108826_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/COPD.S423993","article-title":"Real-World disease burden and healthcare resource utilization among patients with COPD and asthma using triple therapy (FF\/UMEC\/VI) in the United States","volume":"19","author":"Igboekwe","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"18","key":"10.1016\/j.rmed.2026.108826_bib15","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108826_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/COPD.S337668","article-title":"Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI) following a COPD exacerbation","volume":"17","author":"Mannino","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"10.1016\/j.rmed.2026.108826_bib17","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1007\/s12325-024-02999-3","article-title":"Fluticasone Furoate\/Umeclidinium\/Vilanterol initiation following a COPD exacerbation: benefits of prompt initiation on COPD outcomes","volume":"41","author":"Mannino","year":"2024","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2026.108826_bib18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12325-023-02776-8","article-title":"Outcomes of patients with COPD treated with ICS\/LABA before and after Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI)","volume":"41","author":"McCormack","year":"2024","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108826_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/COPD.S386962","article-title":"Healthcare resource utilization, cost and clinical outcomes in patients diagnosed with COPD initiating tiotropium Bromide\/Olodaterol versus fluticasone Furoate\/Umeclidinium\/Vilanterol based on exacerbation history","volume":"18","author":"Sethi","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"10.1016\/j.rmed.2026.108826_bib21","first-page":"791","article-title":"Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide\/olodaterol or fluticasone furoate\/umeclidinium\/vilanterol","volume":"29","author":"Sethi","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.rmed.2026.108826_bib22","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/COPD.S432963","article-title":"Exacerbations and real-world outcomes after single-inhaler triple therapy of Budesonide\/Glycopyrrolate\/Formoterol fumarate, among patients with COPD: results from the EROS (US) Study","volume":"18","author":"Strange","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2026.108826_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/COPD.S347735","article-title":"PRIMUS - prompt initiation of maintenance therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation","volume":"17","author":"Tkacz","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2026.108826_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2147\/COPD.S302241","article-title":"Development and validation of a healthcare utilization-based Algorithm to identify acute exacerbations of chronic obstructive pulmonary disease","volume":"16","author":"Mapel","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.rmed.2026.108826_bib26","doi-asserted-by":"crossref","first-page":"A4863","DOI":"10.1016\/j.chest.2024.06.2880","article-title":"Trends in treatment initiation of inhaled maintenance medications for copd over the last 7 years","volume":"166","author":"Siddharthan","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00606-2021","article-title":"Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population","volume":"8","author":"Ashdown","year":"2022","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12931-020-1280-y","article-title":"Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis","volume":"21","author":"Bafadhel","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108826_bib29","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2147\/COPD.S374670","article-title":"Benefits of Budesonide\/Glycopyrronium\/Formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post-hoc analysis of data from ETHOS","volume":"17","author":"Bafadhel","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.rmed.2026.108826_bib30","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108826_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12890-025-03898-1","article-title":"Progression from GOLD A\/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapy","volume":"25","author":"Siddharthan","year":"2025","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2026.108826_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106509","article-title":"Benefits of budesonide\/glycopyrrolate\/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial","volume":"185","author":"Martinez","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108826_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211034329","article-title":"Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial","volume":"15","author":"Rabe","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"7","key":"10.1016\/j.rmed.2026.108826_bib35","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1513\/AnnalsATS.201508-493OC","article-title":"Validation of a new risk measure for chronic obstructive pulmonary disease exacerbation using health insurance claims data","volume":"13","author":"Stanfford","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2026.108826_bib36","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2147\/COPD.S155773","article-title":"Development and validation of a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data","volume":"13","author":"Annavarapu","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.rmed.2026.108826_bib37","first-page":"572","article-title":"Decrease in exacerbations during the coronavirus disease 2019 pandemic in a cohort of veterans with COPD","volume":"8","author":"Trujillo","year":"2021","journal-title":"Chronic Obstr Pulm Dis"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:04:28Z","timestamp":1784934268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"alternative-id":["S0954611126001940"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108826","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients with COPD before and after initiation of treatment with budesonide\/glycopyrrolate\/formoterol fumarate: Results from the US ARCTOS study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108826"}}